寡聚苯乙炔修饰RM26的177Lu标记和细胞内化研究

doi:10.7538/tws.2022.35.03.0200

摘要/Abstract

摘要： 促胃泌素多肽受体（gastrin-releasing peptide receptor, GRPR）在多种肿瘤细胞中过度表达，可以被GRPR拮抗剂靶向。高的细胞内化率有助于提高放射性治疗药物的治疗效果，减少给药剂量。激动剂的内化率优于拮抗剂，但是严重的副作用限制了激动剂的应用。将具有跨膜能力的寡聚苯乙炔（OPE）和GRPR拮抗剂RM26偶联，可以提高拮抗剂的内化能力。本研究合成了两种多功能化合物NOTA-OPE-1-RM26和NOTA-OPE-2-RM26，分别进行¹⁷⁷Lu标记，得到了高放化纯度的标记物。标记化合物¹⁷⁷Lu-NOTA-OPEs-RM26在生理盐水、高糖培养液、新生牛血清中稳定存在。体外稳定性实验表明，引入OPE-1少量增加了化合物的内化率，而引入OPE2显著增加了化合物的内化率。此外，引入OPE并没有改变RM26的特异性结合能力。实验结果表明，引入跨膜基团提高拮抗剂药物细胞内化率可行。

关键词: ¹⁷⁷Lu, RM26多肽, 寡聚苯乙炔, 内化率

Abstract: Gastrin releasing peptide receptor (GRPR) is overexpressed in various tumors, and these GRPR-positive tumors have successfully and widely been targeted with GRPR antagonists. To achieve a good therapeutic effectiveness and less radioactive dosage administration, high cellular internalization is required. The cellular internalization of agonists is better than that of antagonists, but the severe side effects of agonists restrict their applications. In this study, we hypothesized that introducing membrane penetrating oligo-phenylene-ethynylene (OPE) to GRPR antagonist RM26 could increase the cellular internalization of antagonists. Therefore, two multi-functional compounds NOTA-OPE-1-RM26 and NOTA-OPE-2-RM26 were synthesized and labelled with 177Lu with high efficiency. The ¹⁷⁷Lu labelled compounds ¹⁷⁷Lu-NOTA-OPEs-RM26 were stable in saline, dulbecco’s modified eagle medium (DMEM) and newborn bovine serum. The in vitro experimental results indicated that the introduction of OPE-1 slightly increased the cellular internalization of the radiolabelled compounds while OPE-2 significantly increased the cellular internalization. In addition, the introduction of OPEs did not change the specific binding ability of RM26. The investigations indicated that introducing the OPE to increase the internalization was feasible.

Key words: ¹⁷⁷Lu, RM26 peptide, oligo-phenylene-ethynylene, internalization

廖伟, 付华霞, 李祥玉, 阚文涛, 杨夏, 王静, 赵鹏, 卓连刚, 杨宇川, 魏洪源. 寡聚苯乙炔修饰RM26的¹⁷⁷Lu标记和细胞内化研究[J]. 同位素, 2022, 35(3): 200-208.

LIAO Wei, FU Huaxia, LI Xiangyu, KAN Wentao, YANG Xia, WANG Jing, ZHAO Peng, ZHUO Liangang, YANG Yuchuan, WEI Hongyuan. ¹⁷⁷Lu Radiolabeling of RM26 Modified with Oligo-Phenylene-Ethynylene and its Cellular Internalization[J]. Journal of Isotopes, 2022, 35(3): 200-208.

参考文献

［1］Cornelio D B, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy［J］. Ann Oncol, 2007, 18(9): 1457-1466.
［2］Markwalder R, Reubi J C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation［J］. Cancer Research, 1999, 59(5): 1152-1159.
［3］Baratto L, Duan H, Mcke H, et al. Imaging the distribution of gastrin-releasing peptide receptors in cancer［J］. Journal of Nuclear Medicine, 2020, 61(6): 792-798.
［4］Opalinska M, Hubalewska-Dydejczyk A, Sowa-Staszczak A. Radiolabeled peptides: current and new perspectives［J］. J Nucl Med Mol Imaging, 2017, 61(2): 153-167.
［5］Cona M M, Wang H, Li J, et al. Continuing pursuit for ideal systemic anticancer radiotherapeutics［J］. Investigational New Drugs, 2012, 30(5): 2050-2065.
［6］Uusijrvi H, Bernhardt P, Ericsson T, et al. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution［J］. Med Phys, 2006, 33(9): 3260-3269.
［7］Goddu S M, Howell R W, Rao D V. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and Svalues for radionuclides uniformly distributed in different cell compartments［J］. Journal of Nuclear Medicine, 1994, 35(2): 303-316.
［8］Goddu S M, Howell R W, Rao D V. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides［J］. Journal of Nuclear Medicine, 1994, 35(3): 521-530.
［9］Maina T, Nock B A, Kulkarni H, et al. Theranostic prospects of gastrin-releasing peptide receptor-radioantagonists in oncology［J］. PET Clin, 2017, 12(3): 297-309.
［10］Baratto L, Jadvar H, Iagaru A. Prostate cancer theranostics targeting gastrin-releasing peptide receptors［J］. Mol Imaging Biol, 2018, 20(4): 501-509.
［11］Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors［J］. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(44): 16436-16441.
［12］Lymperis E, Kaloudi A, Kanellopoulos P, et al. Comparative evaluation of the new GRPR-antagonist¹¹¹In-SB9 and ¹¹¹In-AMBA in prostate cancer models: implications of in vivo stability［J］. J Labelled Comp Radiopharm, 2019, 62(10): 646-655.
［13］Zhong Z, Kan W, Liao W. Cellular internalization of a cell-penetrating peptide conjugated gastrin-releasing peptide receptor antagonist［J］. Journal of Radioanalytical and Nuclear Chemistry, 2019, 319(3): 1201-1206.
［14］Wang Y, Tang Y, Zhou Z, et al. Membrane perturbation activity of cationic phenylene ethynylene oligomers and polymers: selectivity against model bacterial and mammalian membranes［J］. Langmuir, 2010, 26: 12509-12514.
［15］Wang Y, Chi E Y, Schanze K S, et al. Membrane activity of antimicrobial phenylene ethynylene based polymers and oligomers［J］. Soft Matter, 2012, 8(33): 8547-8558.
［16］Hill E H, Stratton K, Whitten D G, et al. Molecular dynamics simulation study of the interaction of cationic biocides with lipid bilayers: aggregation effects and bilayer damage［J］. Langmuir, 2012, 28: 14849-14854.
［17］Wang J, Zhuo L, Liao W, et al. Assessing the biocidal activity and investigating the mechanism of oligopphenylene-ethynylenes［J］. ACS Applied Materials & Interfaces, 2017, 9: 7964-7971.
［18］Mitran B, Rinne S S, Konijnenberg M W, et al. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷Lu-DOTAGA-PEG(2) -RM26［J］. International Journal of Cancer, 2019, 145(12): 3347-3358.
［19］Mitran B, Thisgaard H, Rosenstr-m U, et al. High contrast PET imaging of GRPR expression in prostate cancer using cobalt-labeled bombesin antagonist RM26［J］. Contrast Media & Molecular Imaging, 2017, 2017: 6873684.
［20］Varasteh Z, Velikyan I, Lindeberg G, et al. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging［J］. Bioconjugate Chemistry, 2013, 24(7): 1144-1153.
［21］Mansour N, Paquette M, Ait-Mohand S, et al. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: ［64Cu］-DOTHA2-PEG-RM26［J］. Nuclear Medicine and Biology, 2018, 56: 31-38.
［22］Lundmark F, Abouzayed A, Mitran B, et al. Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer-optimization of the affinity towards PSMA by linker modification in murine model［J］. Pharmaceutics, 2020, 12(7): 614.
［23］Dalm S U, Nonnekens J, Doeswijk G N, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models［J］. Journal of Nuclear Medicine, 2016, 57(2): 260-265.
［24］Jiménez-Mancilla N, Ferro-Flores G, Santos-Cuevas C, et al. Multifunctional targeted therapy system based on 99mTc/177Lu-labeled gold nanoparticles-Tat(49-57)-Lys3-bombesin internalized in nuclei of prostate cancer cells［J］. J Labelled Comp Radiopharm, 2013, 56(13): 663-671.
［25］Das S, Al-Toubah T, ElHaddad G, et al. ¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors［J］. Expert Rev Gastroenterol Hepatol, 2019, 13(11): 1023-1031.
［26］Pan D, Yan Y, Yang R, et al. PET imaging of prostate tumors with ¹⁸F-Al-NOTA-MATBBN［J］. Contrast Media & Molecular Imaging, 2014, 9(5): 342-348.
［27］Liao W, Zhuo L G, Yang X, et al. Biocidal activity and mechanism study of unsymmetrical oligo-phenylene-ethynylenes［J］. ACS Applied Bio Materials, 2020, 3(9): 5644-5651.
［28］Liu Y, Hu X, Liu H, et al. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2013, 54(12): 2132-2138.

[1]	杨宇川, 阚文涛, 杨夏, 魏洪源, 卓连刚, 王静, 廖伟, 赵鹏, 王关全. ¹⁷⁷Lu放射性治疗药物研究新进展[J]. 同位素, 2022, 35(3): 164-178.
[2]	卓连刚, 杨宇川, 岳海东, 熊晓玲, 王关全, 王海麟, 杨林, 林青川, 陈琪萍, 涂俊, 魏洪源. DGA树脂辅助的循环淋洗技术制备无载体镥［¹⁷⁷Lu］[J]. 同位素, 2022, 35(3): 217-223.
[3]	麻广宇, 巴建涛, 彭程, 陈英茂. ¹⁷⁷Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展[J]. 同位素, 2022, 35(2): 128-134.
[4]	马秀凤;张君丽;李洪玉;梁积新;杨云;杨春慧;杜进. ¹⁷⁷Lu标记单克隆抗体Rituximab[J]. 同位素, 2014, 27(2): 98-103.
[5]	邓新荣 ;向学琴 ;李凤林 ;樊彩云 ;刘子华 ;陈阳 ;罗志福 . ¹⁷⁷Lu-DOTMP在荷瘤小鼠体内的生物分布和兔SPECT显像研究[J]. 同位素, 2012, 25(3): 160-164.
[6]	梁积新 ;李洪玉 ;向学琴 ;罗洪义 ;胡连生 ;邓新荣 ;陈阳 ;庄玲 ;罗志福 . 神经肽类似物DOTA-Substance P的¹⁷⁷Lu标记及其生物分布 [J]. 同位素, 2012, 25(2): 65-70.
[7]	邓新荣 ;杜进 ;翟士桢 ;沈亦佳 ;罗志福 . 奥曲肽-葡聚糖-亲和素的偶联及其与¹⁷⁷Lu-DTPA-BIS-BIOTIN的体外结合[J]. 同位素, 2011, 24(3): 146-150.
[8]	柳银黎;尹光荣;付博;叶肇云;王晓静. ¹⁷⁷Lu-EDTMP放化纯度分析方法的建立[J]. 同位素, 2010, 23(3): 163-165.
[9]	李洪玉 ;梁积新 ;向学琴 ;邓新荣 ;郑德强 ;罗洪义 ;陈阳 ;刘海春 ;鲁佳 ;罗志福 . ¹⁷⁷Lu-EDTMP的药盒法制备、大鼠体内生物分布及显像[J]. 同位素, 2010, 23(2): 65-70.
[10]	史继云;余子璘;贾兵;赵慧云;王凡. ¹⁷⁷Lu-DOTA-Bz-RGD dimer和¹⁷⁷Lu-DOTA-Bz-PEG4-RGD dimer的制备及生物评价[J]. 同位素, 2007, 20(4): 214-218.

寡聚苯乙炔修饰RM26的¹⁷⁷Lu标记和细胞内化研究

¹⁷⁷Lu Radiolabeling of RM26 Modified with Oligo-Phenylene-Ethynylene and its Cellular Internalization

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics